Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 618 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: blood transfusion Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Luspatercept + Darbepoetin in MDS

NCT07096297
View directory record Official record
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
Luspatercept, Darbeopoetin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

NCT02908516
View directory record Official record
Conditions
Hip Fractures, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial Comparing a Conservative Management and Laser Surgery

NCT01220011
View directory record Official record
Conditions
Blood and Blood Disorders, Anemia, Neonatal, Hematologic Disease, Infant, Newborn, Diseases
Interventions
Fetoscopic laser surgery
Procedure
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Other
Eligibility
18 Years and older · Female only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
Aurora, Colorado • Baltimore, Maryland • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Active, not recruiting Phase 4 Interventional

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

NCT03063892
View directory record Official record
Conditions
Hip Fractures
Interventions
Tranexamic Acid (TXA), Saline solution
Drug
Lead sponsor
Gregory M Georgiadis MD
Other
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

NCT01566695
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Oral Azacitidine, Placebo, Best Supportiv Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 14, 2026, 9:55 PM EDT
Withdrawn Not applicable Interventional

Blood Conservation in Cardiac Surgery

NCT01463345
View directory record Official record
Conditions
Transfusion Reactions, Post Cardiac Surgery
Interventions
Blood transfusion
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

NCT01584531
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)

NCT05444894
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Hemoglobinopathies, Thalassemia Major, Thalassemia Intermedia
Interventions
EDIT-301
Genetic
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
18 Years to 35 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

NCT00067080
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting Phase 2 Interventional

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

NCT03587272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers

NCT01589666
View directory record Official record
Conditions
Coagulation Defects
Interventions
Spray-dried S/D-treated Plasma, Spray-dried S/D-treated plasma
Biological · Drug
Lead sponsor
Entegrion, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of G6PD Deficiency on Red Blood Cell Storage

NCT04081272
View directory record Official record
Conditions
G6PD Deficiency
Interventions
Sodium Chromate Cr51
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 2 Interventional Results available

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

NCT00901199
View directory record Official record
Conditions
Thalassemia, Iron Overload
Interventions
Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)
Drug
Lead sponsor
Elliott Vichinsky
Other
Eligibility
8 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational

Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

NCT02561312
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S
Interventions
Rapid manual partial exchange transfusion, Simple Transfusion
Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Not applicable Interventional Results available

TXA Study in Major Burn Surgery

NCT02753816
View directory record Official record
Conditions
Tranexamic Acid, Burn, Major Surgery
Interventions
Tranexamic Acid, Placebo Comparator
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06763341
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, PCNA Inhibitor AOH1996, Venetoclax
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational

Thromboelastography-Guided Fluid Management in Spinal Surgery

NCT03999086
View directory record Official record
Conditions
Spinal Fusion
Interventions
Intervention, Control Group
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Not applicable Interventional Results available

Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)

NCT03329404
View directory record Official record
Conditions
Transfusion Dependent Thalassemia
Interventions
Mirasol Red Blood Cells (MIR RBCs), Reference Red Blood Cells (REF RBCs)
Device
Lead sponsor
Terumo BCTbio
Industry
Eligibility
12 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Oakland, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 14, 2026, 9:55 PM EDT
Completed No phase listed Observational

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

NCT01913548
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Not listed
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
16 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
6
States / cities
Oakland, California • Augusta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

NCT05284032
View directory record Official record
Conditions
Platelet Refractoriness, Hematologic Malignancy
Interventions
isatuximab 10 mg/kg
Drug
Lead sponsor
Firas El Chaer, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 14, 2026, 9:55 PM EDT
Terminated No phase listed Observational

Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

NCT04614987
View directory record Official record
Conditions
Neurotoxicity
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 14, 2026, 9:55 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Cold Apheresis Platelets in PAS

NCT02754414
View directory record Official record
Conditions
Platelet Transfusion
Interventions
Apheresis platelet collection, Refrigerated storage of apheresis platelets in PAS/plasma, Infusion of aliquot of autologous radiolabeled platelets, In vitro tests
Procedure · Other · Radiation
Lead sponsor
Bloodworks
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 14, 2026, 9:55 PM EDT
Recruiting Phase 2 Interventional

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

NCT04419649
View directory record Official record
Conditions
Myelodysplastic Syndromes, Cytopenia
Interventions
Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
11
States / cities
Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 14, 2026, 9:55 PM EDT
Completed Phase 3 Interventional

Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial

NCT04684719
View directory record Official record
Conditions
Hemorrhagic Shock, Traumatic Injury
Interventions
low titer whole blood, Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
18 Years to 89 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Louisville, Kentucky • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 14, 2026, 9:55 PM EDT